Brief: Tracon Pharma - Cash & Cash Equivalents Were $13.6 Million At June 30, 2022, Compared To $24.1 Million At December 31, 2021 & Expected To Fund Co Into 2023
10/08/2022 21:16
Aug 10 (Reuters) - TRACON Pharmaceuticals Inc TCON.O :
* TRACON PHARMACEUTICALS REPORTS SECOND QUARTER 2022
FINANCIAL
RESULTS AND PROVIDES CORPORATE UPDATE
* TRACON PHARMA - CASH & CASH EQUIVALENTS WERE $13.6 MILLION
AT
JUNE 30, 2022, COMPARED TO $24.1 MILLION AT DECEMBER 31, 2021 &
EXPECTED TO FUND CO INTO 2023
* QTRLY LOSS PER SHARE $0.31
* Q2 EARNINGS PER SHARE VIEW $-0.37 -- REFINITIV IBES DATA
Source text for Eikon: ID:nGNX9mJTln
Further company coverage: TCON.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on TRACON Pharmaceuticals
See all newsBrief: TRACON Pharmaceuticals Says ENVASARC Trial ORR Is 5%, Does Not Meet 11% Endpoint
Tracon Pharmaceuticals Inc Reports Results For The Quarter Ended In March: Earnings Summary
Tracon Pharmaceuticals Inc Expected To Post A Loss Of $1.19 A Share: Earnings Preview
Tracon Pharmaceuticals Inc Expected To Post A Loss Of $1.19 A Share: Earnings Preview
Brief: Tracon Pharmaceuticals Files For Offering Of Common Stock, Pre-Funded Warrants